Ona Therapeutics raises $86.6 million for two ADCs targeting treatment-resistant cancers

Ona Therapeutics, a global biopharmaceutical company pioneering first-in-class antibody-drug conjugates (ADCs) to address treatment-resistant cancers, announced the closing of an oversubscribed $86.6 million Series B financing. The round was co-led by new investors Columbus Venture Partners and Méri...